Funding for this research was provided by:
Received: 16 December 2021
Accepted: 12 May 2022
First Online: 20 May 2022
: All methods were carried out in accordance with relevant guidelines and regulations. All study activities and protocols received ethics approval and all patients provided written informed consent. Please see Supplemental Table InternalRef removed for a list of IRBs and approval dates.
: CJ (University of Southampton), HB (ICON plc), SC (Mapi Research Trust), and SN (ICON Clinical Research GmbH) received consultancy fees from AstraZeneca and Merck & Co, Inc. SA, HKY, and NP are employees of AstraZeneca; SJ is an employee of Merck & Co, Inc. All other authors report no conflict of interest.